Omzet 2024 * | 17,57 mln. 16,41 mln. | Omzet 2025 * | 29,87 mln. 27,9 mln. | Marktkapitalisatie | 54,82 mln. 51,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -35 mln. -32,7 mln. | Nettowinst (verlies) 2025 * | -16 mln. -14,95 mln. | EV/omzet 2024 * | 3,12 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,84 x |
K/w-verhouding 2024 * |
-2,29
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 100% |
Recentste transcriptie over BioLineRX Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24-05-09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01-01-09 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24-02-14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01-01-10 |
Aharon Schwartz
CHM | Chairman | 80 | 01-01-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 112 mld. | |
+5,07% | 22,94 mld. | |
-12,75% | 22,22 mld. | |
-9,86% | 17,02 mld. | |
-14,97% | 16,88 mld. | |
-39,94% | 16,87 mld. | |
+2,80% | 13,63 mld. | |
+27,39% | 11,61 mld. |